Gestational trophoblastic neoplasia other diagnostic studies

Revision as of 20:05, 11 March 2019 by Skazmi (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Gestational trophoblastic neoplasia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Gestational trophoblastic neoplasia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Gestational trophoblastic neoplasia other diagnostic studies On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Gestational trophoblastic neoplasia other diagnostic studies

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Gestational trophoblastic neoplasia other diagnostic studies

CDC on Gestational trophoblastic neoplasia other diagnostic studies

Gestational trophoblastic neoplasia other diagnostic studies in the news

Blogs on Gestational trophoblastic neoplasia other diagnostic studies

Directions to Hospitals Treating Gestational trophoblastic neoplasia

Risk calculators and risk factors for Gestational trophoblastic neoplasia other diagnostic studies

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Syed Hassan A. Kazmi BSc, MD [2]

Overview

2-[F-18]fluoro-2-deoxy-D-glucose (FDG)-PET scanning may be used to study the extent of malignancy in gestational trophoblastic neoplasia.

Other Diagnostic Studies

2-[F-18]fluoro-2-deoxy-D-glucose (FDG)-PET Scan

References

  1. Sironi, S; Picchio, M; Mangili, G; Garavaglia, E; Zangheri, B; Messa, C; Voci, C; Taccagni, G.L; Maschio, A.Del; Fazio, F (2003). "[18f]fluorodeoxyglucose positron emission tomography as a useful indicator of metastatic gestational trophoblastic tumor: preliminary results in three patients". Gynecologic Oncology. 91 (1): 226–230. doi:10.1016/S0090-8258(03)00437-2. ISSN 0090-8258.
  2. Hebart, H.; Erley, C.; Kaskas, B.; Mayer, R.; Konig, M.; Einsele, H.; Bokemeyer, C.; Meerpohl, H. G.; Feine, U.; Kanz, L. (1996). "Positron emission tomography helps to diagnose tumor emboli and residual disease in chonocarcinoma". Annals of Oncology. 7 (4): 416–418. doi:10.1093/oxfordjournals.annonc.a010611. ISSN 0923-7534.
  3. Numnum, T. Michael; Leath, Charles A.; Straughn, J. Michael; Conner, Michael G.; Barnes, Mack N. (2005). "Occult choriocarcinoma discovered by positron emission tomography/computed tomography imaging following a successful pregnancy". Gynecologic Oncology. 97 (2): 713–715. doi:10.1016/j.ygyno.2005.01.049. ISSN 0090-8258.

Template:WH Template:WS